Abstract:
Liver transplantation represents a chief therapeutic approach for acute liver failure, end-stage liver disease and hepatocellular carcinoma. Despite witnessing advancements in short- and medium-term survival over recent decades, attributed to refinements in surgical techniques and immunosuppressive protocols, long-term mortality remains impervious to modification. Notably, cardiovascular disease emerges as a predominant cause of mortality among liver transplant recipients. This trend is accentuated by the increasing prominence of non-alcoholic steatohepatitis-related cirrhosis as an indication for liver transplantation. Moreover, the administration of immunosuppressive agents is intricately linked to the degradation of the metabolic profile in liver transplant recipients, thereby contributing to the initiation or exacerbation of cardiovascular risk factors, such as hypertension, diabetes, and dyslipidaemia. In addition, the post-liver transplantation period is marked by a decline in lifestyle quality and a failure to acknowledge the psychological distress experienced by patients throughout the transplant process. These factors can precipitate a deterioration in the patient\'s metabolic profile, exacerbated by suboptimal therapeutic compliance. This narrative review aims to comprehensively address the principal metabolic disorders intricately associated with liver transplantation.
摘要:
肝移植是急性肝衰竭的主要治疗方法,终末期肝病和肝细胞癌。尽管见证了近几十年来短期和中期生存的进步,归因于外科技术和免疫抑制方案的改进,长期死亡率仍然无法改变。值得注意的是,心血管疾病成为肝移植受者死亡的主要原因.非酒精性脂肪性肝炎相关肝硬化作为肝移植的指征越来越突出,加剧了这一趋势。此外,免疫抑制剂的给药与肝移植受者代谢谱的降解密切相关,从而导致心血管危险因素的开始或恶化,比如高血压,糖尿病,和血脂异常.此外,肝移植后时期的特点是生活方式质量下降,并且未能承认患者在整个移植过程中所经历的心理困扰.这些因素会导致患者的代谢状况恶化,因治疗依从性欠佳而加剧。这篇叙述性综述旨在全面解决与肝移植相关的主要代谢紊乱。